February 8, 2021

Dear Friedreich's Ataxia Community:

On behalf of all of us at Reata, I extend my appreciation to you for the letter and accompanying information dated February 5, 2021. I have personally reviewed every page of the materials you provided, as have the members of Reata's leadership team. We are deeply moved by the many testimonials from patients and their families, by the insights and new analyses from Friedreich's ataxia (FA) researchers and physicians, and by the sense of urgency from patient advocates around the world. I want to assure you that, even in the face of last year's events, we are dedicated to securing the regulatory approval necessary to make omaveloxolone available to patients with FA.

We share your perspective that omaveloxolone is a promising potential treatment for FA. We know, too, that it is the FA patient community that has made possible our understanding of omaveloxolone's therapeutic potential. It was this community that first brought FA to Reata's attention. Then, as now, we were moved by the seriousness of the unmet need and by the determination of FA patients, family members, and physicians to foster innovation against this terrible disease. It was this community, FA patients, advocates, and experts, that validated the molecular target of omaveloxolone, Nrf2, as a potential therapeutic target in FA. It was this community that appealed to us to initiate the clinical development of omaveloxolone.

FARA has worked over many years with the U.S. Food and Drug Administration (FDA) to establish and validate endpoints for FA clinical trials. As part of its work with the FDA, FARA and its collaborators have conducted a natural history study involving more than 1,000 FA patients. The data from the natural history study has been critical in designing, and interpreting the results of, clinical trials like MOXIe. FARA has also participated in dozens of FDA meetings and has led a Patient Focused Drug Development meeting, which is intended to provide the FA patient perspective and priorities to the FDA. FARA helped to raise the profile of our development program, which supported recruitment and enrollment of the MOXIe trial. Taken together, these and other FARA-led projects have been crucial to our progress in advancing omaveloxolone to this stage.

Looking ahead, we at Reata will continue to seek a constructive dialogue with the FDA on a path forward for omaveloxolone. We are prepared to complete the preparation of and to submit a New Drug Application for omaveloxolone, if the FDA indicates that the clinical trial package would support their review. Also, we are prepared to conduct a follow-on study to

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
972.865.2219
www.reatapharma.com

expand and further bolster the body of evidence supporting omaveloxolone as a potential therapy in FA.

At Reata, the voice of the patient has always been central to how we approach drug development. You, the FA community, have demonstrated the true impact that patients can have in fostering innovative drug development. We are deeply appreciative of your efforts, and we look forward to working with you and the FDA to find a path to securing the regulatory review and approval necessary to make omaveloxolone available to patients with FA.

Sincerely yours,

Warren Huff
Chairman & Chief Executive Officer